Our research and technology help a growing group of patients affected by disorders in the cerebrospinal fluid dynamics to regain cognitive abilities and stay self sufficient for a longer time in the fall of age. We are mainly addressing diseases related to CSF on the rise in the world’s aging populations.
After almost 40 years of research in the field of assessing cerebrospinal fluid dynamics, the company was founded in 2007. In 2009 the first product was CE-marked and introduced to the market. Since then we have developed a product suite, and the company is certified according to ISO-13485. Likvor AB is located in Umeå, Northern Sweden, and has Swedish owners.
The main offer is our trademarked CELDA System which includes an advanced instrument, a powerful software supporting the most commonly used methods and a bed custom built for these kinds of investigations. Besides that, the offer also includes consumables since all investigations need a single-use tube set.
We are also committed to explore and develop new methods and devices in close collaboration with researchers at Umeå University and Umeå University Hospital.
Maria Wallin Wållberg
Likvor’s CEO since 2009 has a long experience of working with export sales as well as strategic positions in different industries.
Ruth has been investing for social purposes since the early 2000s and is the CEO of Impact Invest Scandinavia. She has a doctorate in economics & management from INDEK, KTH. Ruth holds an MBA from Warwick Business School (UK) and is a trained journalist.
Mattias has worked for 17 years in the pharmaceutical and biotechnology industry, both in large companies such as AstraZeneca and Pfizer and in smaller start-ups. For the past 10 years he has worked with investments in companies in the early stages. He has also served on several corporate boards.
Martin is a serial entrepreneur with experience in business development from several different industries. He has made several successful exits and participated in a regional venture capital company.
Former CEO of Likvor. Kjell has worked with business development in start-ups for 20 years, both as an entrepreneur and as an advisor. He has a background as a researcher in organic chemistry at Umeå University and started his first company as a doctoral student.
Besides supporting us on our mission to increase the quality of life for in aging population, we do have a great business case. Diseases related to CSF are a global phenomenon that will grow bigger and bigger every year. Hospitals and healthcare are in need of better and cutting-edge methods. Likvor AB and the CELDA System can be used for several diseases and is unique when it comes to accuracy, efficiency and usability.
Contact me to learn more.